

# Market Announcement

15 November 2021

---

## PYC Therapeutics Limited (ASX: PYC) – Trading Halt

### Description

The securities of PYC Therapeutics Limited ('PYC') will be placed in trading halt at the request of PYC, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 17 November 2021 or when the announcement is released to the market.

### Issued by

**Belinda Giles**

Adviser, Listings Compliance (Perth)

## REQUEST FOR TRADING HALT

ASX Limited  
Central Park  
152-158 St Georges Terrace  
PERTH WA 6000

Attention; Oma Murad

By email: [tradinghaltspert@asx.com.au](mailto:tradinghaltspert@asx.com.au)

Dear Oma,

### **PYC Therapeutics Limited ('PYC') – Request for Trading Halt**

In accordance with Listing Rule 17.1, PYC requests that an immediate trading halt be placed on its securities pending an announcement to the market regarding the Company's Non-human Primate (NHP) tolerability and safety results.

The Company anticipates that the trading halt will be lifted on or before market open on Wednesday 17 November 2021 by provision of an announcement to ASX regarding the results.

PYC is not aware of any reason why the trading halt should not be granted, nor of any other information relevant to this request.

Yours sincerely

Kevin Hart  
Company Secretary

### **About PYC Therapeutics**

PYC Therapeutics (ASX: PYC) is a pre-clinical stage biotechnology company pioneering a new generation of RNA therapeutics that utilize PYC's proprietary library of naturally derived cell penetrating peptides to overcome the major challenges of current genetic medicines. PYC believes its PPMO (Peptide conjugated Phosphorodiamidate Morpholino Oligomer) technology enables a safer and more effective RNA therapeutic to address the underlying drivers of a range of genetic diseases for which no treatment solutions exist today. The Company is leveraging its leading-edge science to develop a pipeline of novel therapies including three preclinical stage programs focused on inherited eye diseases and a preclinical discovery program focused on neurodegenerative diseases. PYC's discovery and laboratory operations are located in Australia, and its pre-clinical, clinical and regulatory operations are performed in the US. For more information, visit [pyctx.com](http://pyctx.com), or follow us on [LinkedIn](#) and [Twitter](#).

## Forward looking statements

*Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.*

*This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.*

*This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited*

**ENDS**

For further information please contact [info@pyctx.com](mailto:info@pyctx.com)